Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

venetoclax 124Azacitidine 96Cytarabine 71fludarabine 44Specimen Handling 38Cyclophosphamide 38Daunorubicin 27Decitabine 26Biopsy 25Idarubicin 24Granulocyte Colony-Stimulating Factor 21gilteritinib 18Injections 18fludarabine phosphate 17Whole-Body Irradiation 17Melphalan 16Busulfan 16Stem Cell Transplantation 15Mycophenolic Acid 15ivosidenib 13Cladribine 13decitabine and cedazuridine drug combination 12Gemtuzumab 12Tacrolimus 11CPX-351 11X-Rays 10Filgrastim 10revumenib 9enasidenib 9Cyclosporine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myeloid, Acute × olverembatinib × Clear all
NCT04501120 2026-04-29

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Ascentage Pharma Group Inc.

Phase 1/2 Recruiting
682 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡